Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637352 | 1.00 | NPSR1 (0.42) | NPSR1MAPK1MAPTCYP2C9PARP1 | |
| SCHEMBL7402926 | 0.81 | MAPT (0.42) | NPSR1MAPK1MAPTCYP2C9ALDH1A1 | |
| SCHEMBL27698646 | 0.81 | NPSR1 (0.41) | NPSR1MAPK1MAPTCYP2C9ALDH1A1 | |
| SCHEMBL3567699 | 0.80 | CCR1 (0.53) | NPSR1ALDH1A1KDM4EHPGD | |
| SCHEMBL31527671 | 0.79 | MAPT (0.45) | NPSR1MAPK1MAPTCYP2C9ALDH1A1 | |
| SCHEMBL10872794 | 0.79 | NPSR1 (0.44) | NPSR1MAPK1MAPTCYP2C9ALDH1A1 | |
| SCHEMBL1750195 | 0.78 | PARP1 (0.38) | NPSR1MAPK1MAPTPARP1ALDH1A1 | |
| SCHEMBL758549 | 0.77 | TP53 (0.37) | NPSR1MAPK1MAPTPARP1ALDH1A1 | |
| SCHEMBL20606050 | 0.77 | LMNA (0.39) | NPSR1MAPK1MAPTPARP1ALDH1A1 | |
| SCHEMBL22471636 | 0.77 | PARP1 (0.37) | NPSR1MAPK1MAPTPARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104592129-A | Improved method used for preparing ambrisentan | QR PHARMACEUTICALS LTD | 2015-05-06 | — | — | CN | claimed |
| WO-2024130342-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | disclosed |
| CN-115874202-A | Method for producing sulfonyl compounds by electrolytic oxidation of thio compounds | 华东理工大学 | 2023-03-31 | — | — | CN | disclosed |
| US-20220202780-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMA INC. (CA) | 2022-06-30 | — | — | US | disclosed |
| EP-3642199-B1 | BENZOFURANS AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-108137562-B | Pyrazolopyrimidine derivative and use thereof | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-10960003-B2 | Pyrazole pyrimidine derivative and uses thereof | BIOTHERYX, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2020081999-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2020-04-23 | — | — | WO | disclosed |
| CN-108137562-A | Pyrazolopyrimidine derivative and use thereof | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-105025898-B | Histamine H4The yl pyrimidines conditioning agent of benzimidazole 2 of acceptor | 詹森药业有限公司 | 2018-01-23 | — | — | CN | disclosed |
| WO-2002068409-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002040962-A2 | METHODS AND REAGENTS TO REDUCE BACKGROUNDS OF HETEROGENEOUS ASSAYS | BENCHMARK SCIENCE, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| US-5439874-A | Preemergence, postemergence herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | disclosed |
| US-5284820-A | Herbicidal substituted cycloalkenes | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-08 | — | — | US | disclosed |
| EP-0581132-A2 | Substituted Bicyclo[3.1.0]hexanes and their use as herbicide | BAYER AG (DE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0532948-A1 | Substituted cycloalkenes as herbicides | BAYER AG (DE) | 1993-03-24 | — | — | EP | disclosed |
| EP-0273242-A2 | 2-Pyri(mi)dylthio-aryl ether | BAYER AG (DE) | 1988-07-06 | — | — | EP | disclosed |
| EP-0097289-B1 | AZO DYESTUFFS | BAYER AG (DE) | 1986-10-15 | — | — | EP | disclosed |
| EP-0043411-B1 | REACTIVE DISAZO DYESTUFFS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN DYEING AND PRINTING MATERIALS CONTAINING NITROGEN AND/OR HYDROXYLE GROUPS | BAYER AG (DE) | 1984-07-11 | — | — | EP | disclosed |
| EP-0071168-A2 | Water-soluble disazo compounds and bis-(amino-phenoxy)-ethane compounds with fibre reactive groups as tetrazo compounds, process for the preparation of these compounds and the use of the disazo compounds as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202780-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | AR, SHBG, NR5A1 | NPSR1 707/4885MAPK1 3178/4885MAPT 2957/4885 |
| US-10960003-B2 | Pyrazole pyrimidine derivative and uses thereof | IRAK1, IRAK2, IRAK3 | NPSR1 4090/4885MAPK1 285/4885MAPT 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.